The recently reported encouraging results of the RATIFY trial show that combining the unselective TKI midostaurin with intensive chemotherapy results in a survival benefit for FLT3-ITD AML patients, but it is uncertain how much of this effect is due to inhibition of FLT3 as opposed to off-target effects of midostaurin [55]. This evidence concerns the gene FLT3 and acute myeloid leukemia.